Racial differences in the use of extracorporeal photopheresis for mycosis fungoides

Abstract

Background: Extracorporeal photopheresis (ECP) is an effective treatment option for mycosis fungoides (MF) and associated with few systemic side effects.

Objective: We sought to investigate whether there were differences in rates of ECP use between African-American and Caucasian patients with stage III/IV MF.

Methods: We conducted a retrospective review of all patients treated for MF at the Johns Hopkins Hospital main campus outpatient clinic between 1999 and 2011.

Results: We identified 65 patients with stage III or IV disease, 20 African-American and 45 Caucasian. Only 7 of 20 African-American patients (35%) compared with 30 of 45 (66%) of Caucasian patients were treated with ECP (p = 0.029). In addition, ECP was discussed as an option for 45% of African-Americans compared to 82% of Caucasians (p = 0.007). When discussed as an option, African-Americans and Caucasians had identical rates of ECP use (78% vs 81%, p = 0.841).

Conclusions: Differences in rates of ECP use exist among African-American patients when compared to their Caucasian counterparts and may be related to how often ECP is offered as a treatment option. Improving physician awareness of the factors that influence treatment decision making may help diminish discrepancies in treatment regimens among patients with MF.

• Cutaneous T-cell lymphoma
• ECP
• ethnic skin
• mycosis fungoides

Declaration of interest

The authors have no conflicts of interest to declare.

A portion of this work was presented at the National Medical Association Annual Convention and Scientific Assembly 27–31 July 2013 in Toronto, Canada.